Taghizadehghalehjoughi, AliHacimuftuoglu, AhmetCetin, MeltemUgur, Afife BusraGalateanu, BiancaMezhuev, YaroslavAbd El-Aty, A. M.2025-05-102025-05-1020181743-58891748-696310.2217/nnm-2017-03862-s2.0-85050696817https://doi.org/10.2217/nnm-2017-0386https://hdl.handle.net/20.500.14720/6212Hacimuftuoglu, Ahmet/0000-0002-9658-3313; Abd El-Aty, A. M./0000-0001-6596-7907; Stivaktakis, Polychronis/0000-0001-6004-2948; Nalci, Kemal Alp/0000-0003-3786-5246; Tsatsakis, Aristidis/0000-0003-3824-2462Aim: The present study was designed to evaluate the effects of irinotecan hydrochloride (IRI)- or metformin hydrochloride (MET)-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles (NPs) for the treatment of glioblastoma multiforme using in vitro neuron and U-87 MG glioblastoma cell cultures and in vivo animal model. Methods: The cytotoxic and neurotoxic effects of pure drugs, blank NPs and MET- and IRI-loaded PLGA NPs were investigated in vitro (using methylthiazolyldiphenyl-tetrazolium bromide assay) and in vivo (using Cavalieri's principle for estimation of cancer volume). Results: 1 and 2 mM doses of MET and MET-loaded PLGA NPs, respectively, significantly reduced the volume of extracted cancer. Conclusion: Consequently, MET- and IRI-loaded PLGA NPs may be a promising approach for the treatment of glioblastoma multiforme.eninfo:eu-repo/semantics/closedAccessBrain TumorCavalieri'S PrincipleIrinotecanMetforminNanoparticlesPlgaArticle1313Q1Q21595160630028222WOS:000441781300007